CRISPR Therapeutics Reports Promising Phase 1 Clinical Data for CTX310™ and Updates on Cardiovascular Disease Programs
26/6 13:11
CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs....